Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study

Conclusions
Children receiving repeated courses of rituximab for FRSDNS experience an improving clinical response. Side effects appear acceptable, but significant complications can occur. These findings support repeated rituximab use in FRSDNS.

Source: Journal of the American Society of Nephrology : JASN - May 31, 2022 Category: Urology & Nephrology Authors: Chan, E. Y.-h., Yu, E. L. M., Angeletti, A., Arslan, Z., Basu, B., Boyer, O., Chan, C.-Y., Colucci, M., Dorval, G., Dossier, C., Drovandi, S., Ghiggeri, G. M., Gipson, D. S., Hamada, R., Hogan, J., Ishikura, K., Kamei, K., Kemper, M. J., Ma, A. L.-t., Par Tags: Glomerulonephritis and Interstitial Nephritis Source Type: research